CIK 0001699382 · Non-accelerated filer<br>Smaller reporting company
PMV Pharmaceuticals, Inc.
Sign in to watch- Ticker
- PMVP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463218129
- Phone
- (609) 642-6670
- Business address
- 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON, NJ, 08540
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 62 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Eckler Matthew Joseph Director | Grant or award · Stock Option (right to buy) | +84,000 | 84,000 | ||
| 2026-06-04 | FLOWERS KIRSTEN Director | Grant or award · Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2026-06-04 | Stelzer Laurie Director | Grant or award · Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2026-06-04 | BAUM CHARLES M Director | Grant or award · Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2026-06-04 | Gallagher Carol Giltner Director | Grant or award · Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2026-06-04 | Gallagher Carol Giltner Director | Gift · Stock Option (right to buy) | −42,000 | 0 | ||
| 2026-06-04 | Gallagher Carol Giltner Director | Gift · Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2026-06-04 | LEVINE ARNOLD J Director | Grant or award · Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2026-03-05 | Carulli Michael Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +240,000 | 240,000 | ||
| 2026-03-05 | Jalota Deepika Chief Development Officer | Grant or award · Employee Stock Option (right to buy) | +303,310 | 303,310 | ||
| 2026-03-05 | Ticktin Robert General Counsel & COO | Grant or award · Employee Stock Option (right to buy) | +319,270 | 319,270 | ||
| 2026-03-05 | Mack David Henry President and CEO | Grant or award · Employee Stock Option (right to buy) | +744,960 | 744,960 | ||
| 2025-10-27 | Mack David Henry President and CEO | Option exercise | +220,643 | $1.37 | $302K | 451,109 |
| 2025-10-27 | Mack David Henry President and CEO | Option exercise · Employee Stock Option (right to buy) | −220,643 | 0 | ||
| 2025-10-23 | ORBIMED ADVISORS LLC 10% owner | Sale | −1,000,000 | $1.52 | $1.5M | 4,975,291 |
| 2025-09-10 | ORBIMED ADVISORS LLC 10% owner | Sale | −500,000 | $1.80 | $900K | 5,975,291 |
| 2025-07-01 | Ticktin Robert General Counsel & COO | Sale | −23,151 | $1.06 | $25K | 98,695 |
| 2025-07-01 | Jalota Deepika Chief Development Officer | Sale | −33,065 | $1.06 | $35K | 89,959 |
| 2025-07-01 | Carulli Michael Chief Financial Officer | Sale | −28,249 | $1.06 | $30K | 60,146 |
| 2025-07-01 | Mack David Henry President and CEO | Sale | −58,411 | $1.06 | $62K | 536,133 |
Page 1 of 10 · 196 trades